Advertisement


Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab

ESMO Congress 2022

Advertisement

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some cases (Abstract 789O).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
In this confirmatory, multicenter trial, we investigated new adjuvant Cemiplimab in 79 patients with resectable stage II to IV cutaneous squamous cell carcinoma. The impetus for this trial was a pilot study that we conducted among patients with stage III and IV disease at a single institution, MD Anderson, where we found an extraordinary pathologic complete response rate, 55% among 20 patients. The long term follow up from that study was presented at ASCO in 2022 and demonstrated three-year longterm survival. So the impetus for this trial was to confirm those results. We investigated 79 patients over 20 centers in the US, Australia, and Europe. We enrolled patients over about a year and a half timeframe during COVID. What we found in this study was that 50.6% of patients, so 40 out of 79 patients, also had a complete pathologic response to new adjuvant therapy with four doses of Cemiplimab. Another 10 patients had a major pathologic response, so less than or equal to 10% residual viable tumor cells in the specimen, after neoadjuvant therapy. We found 20 patients that had a less complete pathologic response. And there were some patients who were not a valuable, some patients who refused surgery because of dramatic clinical responses. There were also some patients who progressed, although that was the minority. This was a first part of the study, the initial portion. So just looking at the primary endpoint of pathologic, complete response, we do not have longterm follow up data yet, or quality of life outcomes data. These are maturing and look forward to presenting these, but the data so far presented demonstrate significant pathologic responses that we think will be durable. And because of this, we're excited about the longterm follow up. This study was published in the New England Journal of Medicine, and we're excited that it offers an opportunity for patients, a new approach, a novel approach to treating this aggressive disease. In the future, we hope that patients may be selected for less aggressive treatments based on their response to neoadjuvant treatment. There may be patients who don't need radiation after surgery. There may be patients who don't need surgery at all. Hopefully, we'll be able to find biomarkers to help predict responses to treatment better in the future. In the current study, we collected circulating tumor DNA as part of the study, and that can be informative, we hope in the future. But at this point it's still premature to say, who will and who will not respond to this approach, that includes both tumor mutational burden and PDL1 status, both of which we investigated and was not informative in selecting patients for response to treatment.

Related Videos

Kidney Cancer

Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of atezolizumab vs placebo as adjuvant therapy in patients with RCC at increased risk of recurrence after nephrectomy; and CheckMate 914, which compared nivolumab monotherapy or nivolumab combined with ipilimumab vs placebo in patients with localized disease who underwent radical or partial nephrectomy and who are at high risk of relapse. (Abstract LBA4 & LBA66).

Breast Cancer

Laurence Buisseret, MD, PhD, on Triple-Negative Breast Cancer: Chemoimmunotherapy With or Without an Anti-CD73 Antibody

Laurence Buisseret, MD, PhD, of Belgium’s Institut Jules Bordet, discusses phase II results from the SYNERGY trial, which tested first-line chemoimmunotherapy of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer. Although adding oleclumab to durvalumab with chemoimmunotherapy did not increase the clinical benefit rate at week 24, research is ongoing to better understand the mechanisms of response and resistance to this study combination (Abstract LBA17).

Kidney Cancer
Immunotherapy

Axel Bex, MD, PhD, on Renal Cell Carcinoma: Phase III Results With Atezolizumab as Adjuvant Therapy

Axel Bex, MD, PhD, of the Netherlands Cancer Institute, discusses phase III findings from the IMmotion010 study, which evaluated the efficacy and safety of atezolizumab vs placebo in patients with renal cell cancer who are at high risk of disease recurrence following nephrectomy (Abstract LBA66).

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Breast Cancer
Survivorship

Matteo Lambertini, MD, PhD, on Oncofertility Care for Young Women With Breast Cancer

Matteo Lambertini, MD, PhD, of the University of Genova and Policlinico San Martino Hospital, talks about why oncofertility counseling should now be considered mandatory in the care of young women with breast cancer. Among the treatments he recommends offering are oocyte/embryo cryopreservation (or ovarian tissue cryopreservation in those not eligible for gamete cryopreservation); ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy; and long-term follow-up to improve the management of gynecology-related issues faced by these women.

Advertisement

Advertisement




Advertisement